Log In
BCIQ
Print this Print this
 

Verigene C. difficile Test

  Manage Alerts
Collapse Summary General Information
Company Luminex Corp.
Descriptionin vitro diagnostic running on Nanosphere's automated Verigene System which detects the toxin A and B gene sequences of Clostridium difficile.
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentApproved
Standard IndicationInfectious, Diagnostic
Indication DetailsDetect toxin A and B gene sequences of Clostridium difficile
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$58.0M

$58.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/30/2016

$58.0M

$58.0M

0

Get a free BioCentury trial today